Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F21%3AN0000109" target="_blank" >RIV/00064190:_____/21:N0000109 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/21:10425700

Výsledek na webu

<a href="http://dx.doi.org/10.1097/MCP.0000000000000743" target="_blank" >http://dx.doi.org/10.1097/MCP.0000000000000743</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MCP.0000000000000743" target="_blank" >10.1097/MCP.0000000000000743</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases

Popis výsledku v původním jazyce

Purpose of review Matrix metalloproteinases (MMPs) are a family of over 20 zinc-dependent proteases with different biological and pathological activities, and many have been implicated in several diseases. Although nonselective MMP inhibitors are known to induce serious side-effects, targeting individual MMPs may offer a safer therapeutic potential for several diseases. Hence, we provide a concise overview on MMP-12, given its association with pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and other progressive pulmonary fibrosis (PPF), which may also occur in coronavirus disease 2019. Recent findings In asthma, COPD, and PPF, increased MMP-12 levels have been associated with inflammation and/or structural changes within the lungs and negatively correlated with functional parameters. Increased pulmonary MMP-12 levels and MMP-12 gene expression have been related to disease severity in asthma and COPD. Targeting MMP-12 showed potential in animal models of pulmonary diseases but human data are still very scarce. Although there may be a potential role of MMP-12 in asthma, COPD and PPF, several pathophysiological aspects await elucidation. Targeting MMP-12 may provide further insights into MMP-12 related mechanisms and how this translates into clinical outcomes; this warrants further research.

Název v anglickém jazyce

Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases

Popis výsledku anglicky

Purpose of review Matrix metalloproteinases (MMPs) are a family of over 20 zinc-dependent proteases with different biological and pathological activities, and many have been implicated in several diseases. Although nonselective MMP inhibitors are known to induce serious side-effects, targeting individual MMPs may offer a safer therapeutic potential for several diseases. Hence, we provide a concise overview on MMP-12, given its association with pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and other progressive pulmonary fibrosis (PPF), which may also occur in coronavirus disease 2019. Recent findings In asthma, COPD, and PPF, increased MMP-12 levels have been associated with inflammation and/or structural changes within the lungs and negatively correlated with functional parameters. Increased pulmonary MMP-12 levels and MMP-12 gene expression have been related to disease severity in asthma and COPD. Targeting MMP-12 showed potential in animal models of pulmonary diseases but human data are still very scarce. Although there may be a potential role of MMP-12 in asthma, COPD and PPF, several pathophysiological aspects await elucidation. Targeting MMP-12 may provide further insights into MMP-12 related mechanisms and how this translates into clinical outcomes; this warrants further research.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CURRENT OPINION IN PULMONARY MEDICINE

ISSN

1070-5287

e-ISSN

1531-6971

Svazek periodika

27

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

54-60

Kód UT WoS článku

000612723200009

EID výsledku v databázi Scopus

2-s2.0-85097211287